SEC Form 4 · accession 0001127602-18-005201
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pablo Lapuerta
Officer — EVP and CMO
Period of report
Feb 8, 2018
Accepted (ET)
Feb 12, 2018 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 8, 2018 | A | 25,710 | A | — | — | Common Stock | 25,710 | 25,710 | D |
| Stock Option (Right to Buy)F3 | $9.79 | Feb 8, 2018 | A | 72,330 | A | — | Feb 8, 2028 | Common Stock | 72,330 | 72,330 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
- F3Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/8/2019) and vests 1/48th per month for each month of service thereafter.